These Analysts Revise Their Forecasts On Haemonetics After Q3 Earnings

Benzinga

Feb 07

Haemonetics Corporation (NYSE:HAE) reported upbeat earnings for its third quarter on Thursday.

The company posted quarterly earnings of $1.31 per share which beat the analyst consensus estimate of $1.25 per share. The company reported quarterly sales of $338.967 million which beat the analyst consensus estimate of $331.616 million.

Haemonetics raised its FY2026 adjusted EPS guidance from $4.80-$5.00 to $4.90-$5.00.

Haemonetics shares fell 6% to trade at $61.13 on Friday.

These analysts made changes to their price targets on Haemonetics following earnings announcement.

Barrington Research analyst Michael Petusky maintained Haemonetics with an Outperform rating and raised the price target from $93 to $94.
Mizuho analyst Anthony Petrone maintained the stock with an Outperform rating and lowered the price target from $90 to $80.

Considering buying HAE stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609351339"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609351339\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609351339?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-07 01:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609351339","market":"hk","top_or_hot":-1,"title":"These Analysts Revise Their Forecasts On Haemonetics After Q3 Earnings","media":"Benzinga","content":"<html><body><p><strong>Haemonetics Corporation</strong> (NYSE:HAE) reported upbeat earnings for its third quarter on Thursday.</p>\n<p>The company posted quarterly earnings of $1.31 per share which beat the analyst consensus estimate of $1.25 per share. The company reported quarterly sales of $338.967 million which beat the analyst consensus estimate of $331.616 million.</p>\n<p>Haemonetics raised its FY2026 adjusted EPS guidance from $4.80-$5.00 to $4.90-$5.00.</p>\n<p>Haemonetics shares fell 6% to trade at $61.13 on Friday.</p>\n<p>These analysts made changes to their price targets on Haemonetics following earnings announcement.</p>\n<ul>\n<li>Barrington Research analyst Michael Petusky maintained Haemonetics with an Outperform rating and raised the price target from $93 to $94.</li>\n<li>Mizuho analyst Anthony Petrone maintained the stock with an Outperform rating and lowered the price target from $90 to $80.</li>\n</ul>\n<p><strong>Considering buying HAE stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"570\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/06122655/image-140-1024x570.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/06122655/image-140-1024x570.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/06122655/image-140-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/06122655/image-140-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/06122655/image-140.png 1098w\" width=\"1024\"/></figure>\n<p>Photo via Shutterstock</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Revise Their Forecasts On Haemonetics After Q3 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Revise Their Forecasts On Haemonetics After Q3 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2026-02-07 01:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Haemonetics Corporation</strong> (NYSE:HAE) reported upbeat earnings for its third quarter on Thursday.</p>\n<p>The company posted quarterly earnings of $1.31 per share which beat the analyst consensus estimate of $1.25 per share. The company reported quarterly sales of $338.967 million which beat the analyst consensus estimate of $331.616 million.</p>\n<p>Haemonetics raised its FY2026 adjusted EPS guidance from $4.80-$5.00 to $4.90-$5.00.</p>\n<p>Haemonetics shares fell 6% to trade at $61.13 on Friday.</p>\n<p>These analysts made changes to their price targets on Haemonetics following earnings announcement.</p>\n<ul>\n<li>Barrington Research analyst Michael Petusky maintained Haemonetics with an Outperform rating and raised the price target from $93 to $94.</li>\n<li>Mizuho analyst Anthony Petrone maintained the stock with an Outperform rating and lowered the price target from $90 to $80.</li>\n</ul>\n<p><strong>Considering buying HAE stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"570\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/06122655/image-140-1024x570.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/06122655/image-140-1024x570.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/06122655/image-140-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/06122655/image-140-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/06122655/image-140.png 1098w\" width=\"1024\"/></figure>\n<p>Photo via Shutterstock</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HAE","symbol_name":"美国血液技术","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/02/50455074/these-analysts-revise-their-forecasts-on-haemonetics-after-q3-earnings","article_id":"2609351339","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609351339","pubTimestamp":1770398884,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"HAE":"美国血液技术"},"translate_title":"这些分析师在第三季度财报公布后修改了对Haemonetics的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HAE":1.5},"content_text":"Haemonetics Corporation (NYSE:HAE) reported upbeat earnings for its third quarter on Thursday.\nThe company posted quarterly earnings of $1.31 per share which beat the analyst consensus estimate of $1.25 per share. The company reported quarterly sales of $338.967 million which beat the analyst consensus estimate of $331.616 million.\nHaemonetics raised its FY2026 adjusted EPS guidance from $4.80-$5.00 to $4.90-$5.00.\nHaemonetics shares fell 6% to trade at $61.13 on Friday.\nThese analysts made changes to their price targets on Haemonetics following earnings announcement.\n\nBarrington Research analyst Michael Petusky maintained Haemonetics with an Outperform rating and raised the price target from $93 to $94.\nMizuho analyst Anthony Petrone maintained the stock with an Outperform rating and lowered the price target from $90 to $80.\n\nConsidering buying HAE stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}